Curis, Inc. Presents CUDC-305 Preclinical Data at the American Association for Cancer Research 100th Annual Meeting 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced data provided in two presentations on the Company’s Hsp90 development candidate, CUDC-305. These presentations were given by Curis scientists at the American Association for Cancer Research (AACR) 100th Annual Meeting 2009, which is being held in Denver, Colorado from April 18-22.

Back to news